Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and DLI for Post-Transplant B-ALL
NCT03982992Phase 2Withdrawn
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Ludwig Maximilian University of Munich. Planned start Jun 2019; status: withdrawn.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03982992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982992.